The Manufacturers Life Insurance Company Makes New $38,000 Investment in Renovaro Inc. (NASDAQ:RENB)

The Manufacturers Life Insurance Company acquired a new stake in shares of Renovaro Inc. (NASDAQ:RENB) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 45,797 shares of the company’s stock, valued at approximately $38,000.

Other hedge funds have also recently modified their holdings of the company. Voya Investment Management LLC purchased a new position in Renovaro in the 4th quarter valued at approximately $30,000. Price T Rowe Associates Inc. MD lifted its stake in shares of Renovaro by 183.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 45,198 shares of the company’s stock valued at $38,000 after purchasing an additional 29,253 shares during the period. SG Americas Securities LLC increased its holdings in Renovaro by 193.3% during the 4th quarter. SG Americas Securities LLC now owns 51,725 shares of the company’s stock valued at $43,000 after acquiring an additional 34,090 shares in the last quarter. Corebridge Financial Inc. raised its stake in Renovaro by 114.8% in the 4th quarter. Corebridge Financial Inc. now owns 57,495 shares of the company’s stock valued at $48,000 after purchasing an additional 30,727 shares during the last quarter. Finally, Wells Fargo & Company MN grew its position in shares of Renovaro by 224.9% in the fourth quarter. Wells Fargo & Company MN now owns 59,101 shares of the company’s stock valued at $49,000 after purchasing an additional 40,912 shares during the period. Hedge funds and other institutional investors own 71.41% of the company’s stock.

Renovaro Stock Down 1.9%

Renovaro stock opened at $0.32 on Tuesday. The firm has a fifty day moving average of $0.45 and a 200-day moving average of $0.74. The firm has a market capitalization of $50.12 million, a P/E ratio of -0.34 and a beta of 0.62. Renovaro Inc. has a 52-week low of $0.29 and a 52-week high of $2.34.

Renovaro (NASDAQ:RENB) last released its quarterly earnings data on Wednesday, February 19th. The company reported ($0.02) EPS for the quarter.

Renovaro Profile

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.